Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mangoceuticals (MGRX) Shares Outstanding (Diluted Average) (2023 - 2025)

Historic Shares Outstanding (Diluted Average) for Mangoceuticals (MGRX) over the last 3 years, with Q3 2025 value amounting to $11.5 million.

  • Mangoceuticals' Shares Outstanding (Diluted Average) rose 47225.15% to $11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year increase of 47225.15%. This contributed to the annual value of $2.0 million for FY2024, which is 8422.66% up from last year.
  • Per Mangoceuticals' latest filing, its Shares Outstanding (Diluted Average) stood at $11.5 million for Q3 2025, which was up 47225.15% from $10.0 million recorded in Q2 2025.
  • Mangoceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $15.8 million during Q2 2023, with a 5-year trough of $1.1 million in Q3 2023.
  • For the 3-year period, Mangoceuticals' Shares Outstanding (Diluted Average) averaged around $5.7 million, with its median value being $2.0 million (2024).
  • In the last 5 years, Mangoceuticals' Shares Outstanding (Diluted Average) plummeted by 8896.82% in 2024 and then surged by 47376.75% in 2025.
  • Quarter analysis of 3 years shows Mangoceuticals' Shares Outstanding (Diluted Average) stood at $1.1 million in 2023, then soared by 84.23% to $2.0 million in 2024, then soared by 482.34% to $11.5 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $11.5 million for Q3 2025, versus $10.0 million for Q2 2025 and $4.6 million for Q1 2025.